Raymond James Financial Services Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-113	Closed	-$6K	–	2888
2018 Q2	$6K	Buy	113 +33	+41%	+$20.9K	﹤0.01%	2759
2018 Q1	$4K	Buy	+80	New	+$49.9K	﹤0.01%	2541
2017 Q1	–	Sell	-400	Closed	-$3K	–	2509
2016 Q4	$3K	Sell	400 -81	-17%	-$73K	﹤0.01%	2341
2016 Q3	$4K	Sell	481 -30	-6%	-$24.1K	﹤0.01%	2301
2016 Q2	$31K	Buy	+511	New	+$556K	﹤0.01%	2198

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Raymond James Financial Services Advisors's TCRT Position: Q3 2023 in Review

Raymond James Financial Services Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 97 shares — an estimated $7.43K sold.

Raymond James Financial Services Advisors first reported a position in TCRT in Q3 2015 and held it in 30 quarters. The position peaked at $1.54M in Q4 2015. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

Raymond James Financial Services Advisors reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 97 Alaunos Therapeutics shares in Q3 2023, an estimated $7.43K.
Raymond James Financial Services Advisors first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 30 quarters.
Raymond James Financial Services Advisors's Alaunos Therapeutics position peaked at $1.54M in Q4 2015.
89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.